arrow
N

Neil Chanchlani

bristol royal hospital for children
H指数:21
被引数:2,898

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Management of Pediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update

儿科克罗恩病的治疗:ECCO-ESPGHAN指南更新

2026-08-190
OAAI
Understanding Anti-TNF Treatment Failure: Pre-Existing Antidrug Antibodies Are Common but Do Not Neutralize Drug Activity In Vitro or Influence Clinical Response to Infliximab or Adalimumab in Patients with Crohn Disease

理解抗TNF治疗失败:预先存在的抗药抗体常见,但无法在体外中和药物活性,也不影响克罗恩病患者对英夫利昔单抗或阿达木单抗的临床反应

2025-10-010
PRE
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
2024-06-0115
OAAI
Neutralising antibody potency against SARS-CoV-2 wild- type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
2023-02-0125
OAAI
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: Results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study
2022-08-2913
OAAI
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

在接受英夫利昔单抗和维多珠单抗治疗的炎症性肠病患者中,两次SARS-CoV-2疫苗剂量后抗体衰减,T细胞免疫和突破性感染

2022-03-1660
OAAI
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients

阿达木单抗和英夫利昔单抗损害SARS-CoV-2抗体反应: 来自11名422生物治疗患者的治疗药物监测研究结果

2021-09-0243
OAAI